Newton Charles W., CFO, reported a transaction classified as grant at Lyell Immunopharma, Inc. involving 112500.000000 shares for an estimated $0.00. Reported holdings after the transaction were 172725.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
Form 4 relationship flags and nearby filing context
Chief Financial Officer
12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subje…
date
Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan.
12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person prov…
The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.
0 other filings
0 recent txs